Breast Cancer Trial, Recruiting (NCT06706570)

Breast Cancer Trial, Recruiting NCT06706570 Sponsor: European Institute of Oncology Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06706570 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You have been diagnosed with breast cancer that has tested positive for estrogen receptors (ER+) and/or progesterone receptors (PgR+), confirmed by a lab test.
Your breast cancer has tested negative for a protein called HER2, based on specific lab tests carried out locally.
Your breast cancer is at an advanced or metastatic stage (meaning it has spread) and you have not yet started treatment for it.
You are willing and able to sign a consent form agreeing to take part in the trial.
You are able to attend follow-up appointments as required by the trial team.

Who may not be able to join:

You have already received treatments for your breast cancer, such as chemotherapy, hormone therapy, or other similar treatments.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nicola Fusco, MD, Istituto Europeo di Oncologia

Phone: 00390294372079

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06706570

Sponsor: European Institute of Oncology

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: 00390294372079

More information: https://clinicaltrials.gov/study/NCT06706570

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You have been diagnosed with breast cancer that has tested positive for estrogen receptors (ER+) and/or progesterone receptors (PgR+), confirmed by a lab test.
Your breast cancer has tested negative for a protein called HER2, based on specific lab tests carried out locally.
Your breast cancer is at an advanced or metastatic stage (meaning it has spread) and you have not yet started treatment for it.
You are willing and able to sign a consent form agreeing to take part in the trial.
You are able to attend follow-up appointments as required by the trial team.

Who may not be able to join:

You have already received treatments for your breast cancer, such as chemotherapy, hormone therapy, or other similar treatments.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

European Institute of Oncology

Registry

ClinicalTrials.gov

Start date

6 November 2024

Est. completion

31 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Evaluation of PIK3CA mutational status: a path towards a "tailored" diagnostic approach.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov